About the Company

Imagin Medical is a medical imaging company

 

Imagin Medical has developed the i/Blue Imaging System to establish a new standard of care in detecting cancers and visualizing the surgical field in minimally invasive surgery. The Company’s initial focus is bladder cancer.

The i/Blue system is expected to improve physicians’ ability to detect bladder cancer and reduce its recurrence by dramatically improving the urologist’s ability to visualize, identify and remove cancerous cells. The Company has completed development of its Alpha Prototype, an advanced optical and light sensor technology that, in conjunction with white light and near-infrared fluorescence, is expected to deliver superior images in less than 15 minutes vs. the full hour required by conventional systems. Imagin believes the time savings will increase the efficiency of the operating room and reduce healthcare costs by potentially enabling procedures to be performed in the less expensive physician’s office.

The company’s products are based on the technology invented by Dr. Stavros Demos while a scientist at the Lawrence Livermore National Laboratory (LLNL). Dr. Demos worked in collaboration with the UC Davis Comprehensive Cancer Center and Dr. Ralph deVere White, one of the world’s leading authorities on bladder cancer, for more than five years to determine feasibility. Imagin has since licensed the technology from LLNL and moved the final stages of development to the University of Rochester’s Laboratory for Laser Energetics (LLE), where Dr. Demos, in the position of Senior Scientist, will continue to support the company through final product development, clinical evaluations and FDA submission.

As the i/Blue Imaging System becomes established in the urology market, the Company will complete development of the i/Vision Imaging System technology which combines multiple illumination sources into one system. The i/Vision will accommodate the most commonly used fluorescing contrast agents and will potentially enable Imagin to expand into additional surgical specialties.

Share This